Kailera Therapeutics
- Health & Biotech
- Waltham, MA, US
- Founded 2024
- Public
- kailera.com
Clinical-stage biopharma developing next-generation injectable and oral GLP-1-based therapies for obesity.
$600MEquity raised in 2025–20262025 $600M · 2026 — · 1 equity round
$1BEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 2 rounds · 2 sources · newest first
Earlier rounds not yet sourced. Kailera Therapeutics was founded in 2024 and raised before Oct 2024; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series BAmount$600MPost-money—✓ Confirmed
- Series AAmount$400MPost-money—◔ Reported
- Earlier rounds not yet sourced
Investors 4
- Bain Capital1
- Adage Capital Management
- CPP Investments
- Royalty Pharma
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Beeline MedicinesHealth · $426M in 2025–2026Shared: Bain Capital, CPP InvestmentsKahuaEnterprise · $250M in 2025–2026Shared: Bain CapitalLegoraAI Apps · $1.3B in 2025–2026Shared: Bain CapitalOratomicDeep Tech · $775M in 2025–2026Shared: Bain CapitalCoralogixEnterprise · $315M in 2025–2026Shared: CPP InvestmentsMerge LabsDeep Tech · $250M in 2025–2026Shared: Bain Capital
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Kailera Therapeutics and its logo are trademarks of their owners, used here for identification only.
